Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.
Prostate Cancer Highlights from ASCO GU, ASCO and EAUN 2022 COR2ED Medical Education: In this podcast Dr Jason Alcorn and Jennifer Sutton discuss the...
COR2ED Medical Education: Prof. Gideon Hirschfield, Professor of Medicine, Division of Gastroenterology, University of Toronto, Canada and Dr Emma Culver, Consultant Hepatologist and Honorary...
COR2ED Medical Education: In this podcast episode, Prof Dimitrios Tsakiris (Haematologist, Basel University, Switzerland) and Assoc. Prof. Michael Nagler (Haematologist, Inselspital University Hospital, Bern,...
